New in Menopause Care: Understanding FDA Approval of Fezolinetant

Topic: New therapy

For decades, the conversation around menopause management has been dominated by a single narrative: hormones. If you were suffering from hot flashes, the gold standard treatment was Hormonal Replacement Therapy (HRT). While effective for many, HRT isn’t an option for everyone—specifically women with a history of breast cancer, blood clots, stroke, or liver disease. For these women, the “gold standard” was out of reach, leaving them to rely on lifestyle tweaks, supplements, or off-label medications with varying degrees of success.

That landscape changed significantly with the FDA’s recent approval of Veozah (fezolinetant), a first-of-its-kind non-hormonal medication designed specifically to treat moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes.

This approval marks a pivotal moment in women’s health. It validates the experience of millions of women who suffer daily and offers a targeted, science-backed solution that doesn’t involve estrogen.

How Hot Flashes Actually Work

To understand why this drug is different, we first need to understand the biology of a hot flash.

For years, we thought hot flashes were simply a result of “low estrogen.” While that’s the trigger, the actual mechanism happens in the brain. Inside your hypothalamus (the brain’s thermostat), there is a delicate balance between estrogen and a brain chemical called neurokinin B (NKB).

• Before Menopause: Estrogen keeps NKB in check. Your internal thermostat works normally.
• During Menopause: Estrogen levels drop. Without that “brake,” NKB activity spikes. This tricks your brain into thinking the body is overheating.
• The Result: Your brain triggers an emergency cooling response—dilating blood vessels (flushing) and sweating profusely—even though you aren’t actually hot.

Enter Fezolinetant: A “Thermostat Reset”

Veozah acts as a neurokinin 3 (NK3) receptor antagonist. In plain English? It blocks the NKB receptor in the brain.

Instead of replacing the missing estrogen (like HRT does), it goes directly to the source of the glitch in the hypothalamus. It effectively tells the brain, “Calm down, we aren’t overheating,” preventing the hot flash from triggering in the first place. This mechanism is precise and non-hormonal, making it a breakthrough for precision medicine in women’s health.

Who Is This Drug For?

The FDA approval covers women experiencing “moderate to severe” vasomotor symptoms. This isn’t just for the occasional warm flush. It is for women whose lives are disrupted by:

• Sleep Disturbance: Waking up soaking wet in the middle of the night (night sweats).
• Social Anxiety: Sudden, visible flushing during meetings or social events.
• Physical Discomfort: Intense heat that causes heart palpitations or chills.

Crucially, because it is non-hormonal, it is a potential option for women who:

• Are comprised by medical history (e.g., history of VTE, stroke, or estrogen-sensitive cancers).
• Older women (>60) who might be outside the safe window for starting HRT.
• Women who simply prefer to avoid hormonal treatments.

What the Clinical Trials Showed

The FDA approval was based on rigorous Phase 3 clinical trials (SKYLIGHT 1 and 2). The results were compelling:

1. Reduction in Frequency: Women saw a significant drop in the number of hot flashes per day compared to placebo.
2. Reduction in Severity: The hot flashes that did occur were less intense.
3. Fast Acting: Improvements were often seen as early as week 1, with full effects stabilizing over time.

Safety and Side Effects

No medication is without risk. The most common side effects reported in trials were abdominal pain, diarrhea, insomnia, back pain, and surprisingly, hot flush (though less frequent).

Important Liver Warning: The FDA has included a warning regarding elevated hepatic transaminases (liver enzymes).

• You will need a blood test to check your liver function before starting the medication.
• Your doctor should monitor your liver enzymes every 3 months for the first 9 months of treatment.
• This ensures that any potential stress on the liver is caught early and managed.

Integrating This Into Your Care Plan

If you are struggling with hot flashes, this approval gives you a new, powerful card to play. It moves the conversation beyond “just deal with it” or “take hormones.”

Questions to ask your doctor:

• “Is my history of [condition] a contraindication for HRT?”
• “Would a neurokinin receptor antagonist be safer for me?”
• “How does the cost/benefit profile of Veozah compare to other non-hormonal options like SSRIs?”

Women’s health is moving towards more options, not fewer. Fezolinetant represents a shift from “managing” symptoms to mechanistically “treating” the root neural cause.